엑셀세라퓨틱스

373110KOSDAQ

46.0 / 100

Reference Date: 2026-10-23

Financial Score13.5 / 40

News Sentiment12.5 / 25

Momentum10.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Slightly up 2.0% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

Excel Therapeutics focuses on the cell culture media market essential for cell and gene therapy (CGT) development, targeting the rapidly growing cell therapy segment, which is projected to expand from $64 billion in 2024 to $306 billion by 2034. The company is diversifying its business into cultivated meat, cosmetics, artificial blood, and other fields, while advancing domestic media production through continuous R&D.

Number of Employees

65people

Average Salary

66.7M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 15.004.0Point

PBR

2.54Industry Average 1.200.0Point

2.1x industry avg (risky)

ROE

-134.41Industry Average 8.000.0Point

Well below industry avg

Debt Ratio

45.55Industry Average 100.006.5Point

Half of industry avg (excellent)

Trend 2023~20253.0 / 10 points

Revenue Growth Rate

3.0 / 3

Avg ▲36.4% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼11.7% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -157.0% (improving, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position1.0Point

Near 52w low (4%, downtrend)

Current 1,050Won52-week high 2,27052-week low 989

1-month return4.0Point

1m +2.04% (slight rise)

Volume trend5.0Point

Volume increasing

Detailed Disclosure

1 totalPositive 0Neutral 1Negative 0

Neutral기타시장안내(관리종목지정우려종목) (시가총액 200억원 미달)2026-10-12